Prescription Pain Medication Market Report 2026

The prescription pain medication market size has grown strongly in recent years. It will grow from $77.22 billion in 2025 to $81.36 billion in 2026 at a compound annual growth rate (CAGR) of 5.4%. The growth in the historic period can be attributed to high prevalence of chronic pain, widespread opioid prescriptions, increasing surgical procedures, aging population, growth in cancer pain cases.

The prescription pain medication market size is expected to see strong growth in the next few years. It will grow to $100.16 billion in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to development of safer pain therapies, rising neuropathic pain incidence, expansion of outpatient care, digital prescription platforms, stricter opioid regulations. Major trends in the forecast period include shift toward non-opioid pain management, rising demand for chronic pain therapies, growth of transdermal and long-acting drugs, expansion of digital and online pharmacies, increased regulatory scrutiny on opioids.

The rising prevalence of arthritis is expected to drive the growth of the prescription pain medication market in the coming years. Arthritis is a condition characterized by inflammation of one or more joints, resulting in pain, swelling, stiffness, and reduced range of motion. Its increasing prevalence is largely linked to obesity, as excess body weight places additional stress on joints - particularly the knees - and promotes inflammation. Prescription pain medications support arthritis management by reducing pain and inflammation, improving joint function, and enhancing overall quality of life for affected individuals. For example, in January 2024, data from the Office for Health Improvement and Disparities, a UK-based government department, reported that in 2023, 18.4% of people aged 16 and over had a long-term musculoskeletal (MSK) condition, up from 17.6% in 2022. Therefore, the growing prevalence of arthritis is driving the growth of the prescription pain medication market.

Major companies operating in the prescription pain medication market are focusing on developing alternative therapies, such as non-opioid painkillers, to address concerns over opioid addiction and improve patient safety. Non-opioid painkillers manage pain without the addictive risks associated with opioids, providing safer and effective options for long-term pain management while reducing the potential for addiction and overdose. For instance, in January 2025, Vertex Pharmaceuticals Incorporated, a US-based biotechnology company, received FDA approval for JOURNAVX, a first-in-class non-opioid oral medication. This drug selectively blocks NaV1.8 sodium channels in peripheral nerves to inhibit pain signals without involving the central nervous system, offering effective acute pain relief without addictive potential. Phase 3 trials in abdominoplasty and bunionectomy demonstrated clinically meaningful pain reduction with a twice-daily dosing regimen, and the medication is not a controlled substance, addressing a critical need for safer acute pain management.

In January 2024, Heron Therapeutics Inc., a US-based biotechnology company, partnered with CrossLink Life Sciences, LLC to expand the sales network for its extended-release local anesthetic, ZYNRELEF. Through this partnership, Heron and CrossLink aim to add approximately 650 sales representatives and promote broader adoption of ZYNRELEF, particularly in orthopedic surgery for post-operative pain management. CrossLink Life Sciences LLC is a US-based company specializing in orthopedic, spine, and sports medicine devices.

Major companies operating in the prescription pain medication market are Mallinckrodt Public Limited Company, Pfizer Inc., Johnson And Johnson, Merck And Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis International AG, GlaxoSmithKline Public Limited Company, Takeda Pharmaceutical Company Limited, Eli Lilly And Company, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Mylan N.V., Sandoz Inc, Bausch Health Companies Inc., Purdue Pharma L.P., Endo International Plc.

North America was the largest region in the prescription pain medication market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prescription pain medication market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the prescription pain medication market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the prescription pain medication market by increasing costs of active pharmaceutical ingredients and excipients, especially for opioid and NSAID formulations. North America and Asia-Pacific have experienced supply delays due to cross-border trade restrictions. On the positive side, tariffs have driven domestic API manufacturing and encouraged diversification of sourcing strategies to reduce long-term dependency on imports.

The prescription pain medication market research report is one of a series of new reports that provides prescription pain medication market statistics, including prescription pain medication industry global market size, regional shares, competitors with a prescription pain medication market share, detailed prescription pain medication market segments, market trends and opportunities, and any further data you may need to thrive in the prescription pain medication industry. This prescription pain medication market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Prescription pain medication refers to drugs that are legally prescribed by a licensed healthcare professional to manage moderate to severe pain. These medications are stronger than over-the-counter (OTC) pain relievers and are used when non-prescription options are insufficient to control pain.

The main types of prescription pain medications include prescription non-steroidal anti-inflammatory drugs (NSAIDs), opioids, anti-epileptic drugs, antidepressants, and other categories. Prescription NSAIDs are medications provided by healthcare professionals to reduce inflammation, alleviate pain, and lower fever by inhibiting cyclooxygenase (COX) enzymes. These drugs can be administered via various routes, including oral, injectable, transdermal, and others. They are used to treat a variety of conditions such as neuropathic pain, cancer pain, post-operative pain, and more. Distribution occurs through hospital pharmacies, retail pharmacies, and online pharmacies.

The prescription pain medication market consists of sales of acetaminophen, antidepressants, anticonvulsants, muscle relaxants, and biologic pain medications. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.